Vicente Pascual

Dr. Vicente Pascual


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Ascensión MarcosAscensión Marcos
Ascensión Marcos
Lluis Serra-MajemLluis Serra-Majem
Lluis Serra-Majem
CMCarmen Marin
Carmen Marin
VPVicente Pascual
Vicente Pascual
FTFrancisco Tinahones
Francisco Tinahones
Ramon EstruchRamon Estruch
Ramon Estruch
There is growing interest in the potential health-related effects of moderate alcohol consumption and, specifically, of beer. This review provides an assessment of beer-associated effects on cardiovascular and metabolic risk factors to identify a consumption level that can be considered “moderate”. We identified all prospective clinical studies and systematic reviews that evaluated the health effects of beer published between January 2007 and April 2020. Five of six selected studies found a protective effect of moderate alcohol drinking on cardiovascular disease (beer up to 385 g/week) vs. abstainers or occasional drinkers. Four out of five papers showed an association between moderate alcohol consumption (beer intake of 84 g alcohol/week) and decreased mortality risk. We concluded that moderate beer consumption of up to 16 g alcohol/day (1 drink/day) for women and 28 g/day (1–2 drinks/day) for men is associated with decreased incidence of cardiovascular disease and overall mortality, among other metabolic health benefits.

1 January 2017 in Clínica e Investigación en Arteriosclerosis
Verified
Journal Article
Closed access
VPVicente Pascual
Vicente Pascual
ASAdalberto Serrano
Adalberto Serrano
JPJuan Pedro-Botet
Juan Pedro-Botet
JAJuan Ascaso
Juan Ascaso
VBVivencio Barrios
Vivencio Barrios
ACAleix Cases
Aleix Cases

24 July 2018 in Clínica e Investigación en Arteriosclerosis
Verified
Journal Article
Open access
ARAntonio Ruiz-García
Antonio Ruiz-García
EAEzequiel Arranz-Martínez
Ezequiel Arranz-Martínez
IMIgnacio Morón-Merchante
Ignacio Morón-Merchante
VPVicente Pascual
Vicente Pascual
JTJuan J. Tamarit
Juan J. Tamarit
JAJuan F. Ascaso
Juan F. Ascaso
Se presenta un documento de consenso del grupo de trabajo de Diabetes de la Sociedad Española de Arteriosclerosis (SEA), basado en los últimos estudios y cambios conceptuales aparecidos. En él se expone el riesgo cardiovascular en la diabetes mellitus tipo 2 (DM2) y las pautas de actuación para la prevención y tratamiento de la enfermedad cardiovascular (ECV) asociada a la DM2. Se consensúa la importancia del control lipídico, basado en el objetivo de colesterol LDL y colesterol no HDL cuando existe hipertrigliceridemia, y el de la presión arterial en la prevención y tratamiento de la ECV. Se revisan los nuevos fármacos hipoglucemiantes y sus efectos sobre la ECV, así como las pautas de tratamiento y control de la hiperglucemia. Así mismo, se considera el uso de las pautas antiagregantes. Se enfatiza la importancia de la actuación global y simultánea sobre todos los factores de riesgo para conseguir una importante reducción de eventos cardiovasculares. Este suplemento está patrocinado por Esteve Pharmaceuticals, S.A. A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Esteve Pharmaceuticals, S.A.

1 July 2019 in Medicina de Familia. SEMERGEN
Verified
Journal Article
Closed access
VPVicente Pascual
Vicente Pascual
PMPablo Perez Martinez
Pablo Perez Martinez
JFJosé Manuel Fernández
José Manuel Fernández
RSRosa Solá
Rosa Solá
VPVicente Pallarés-Carratalá
Vicente Pallarés-Carratalá
EREmilio Ros
Emilio Ros

23 March 2019 in Clínica e Investigación en Arteriosclerosis
Verified
Journal Article
Closed access
VPVicente Pascual
Vicente Pascual
PMPablo Perez Martinez
Pablo Perez Martinez
JFJosé Manuel Fernández
José Manuel Fernández
RSRosa Solá
Rosa Solá
VPVicente Pallarés-Carratalá
Vicente Pallarés-Carratalá
EREmilio Ros
Emilio Ros

Verified
Journal Article
Open access
PDF file
ARAntonio Ruiz-Garcia
Antonio Ruiz-Garcia
VPVicente Pallarés-Carratalá
Vicente Pallarés-Carratalá
ASAdalberto Serrano-Cumplido
Adalberto Serrano-Cumplido
VPVicente Pascual
Vicente Pascual
EAEzequiel Arranz-Martínez Arranz-Martínez
Ezequiel Arranz-Martínez Arranz-Martínez
Carlos EscobarCarlos Escobar
Carlos Escobar
Background/Objectives: Atherosclerotic cardiovascular diseases (ASCVDs) remain the leading cause of morbimortality worldwide. The objectives of this study were to update the prevalence rates of ASCVDs and to evaluate their relationship with cardiovascular–kidney–metabolic (CKM) disorders. Methods: This cross-sectional observational study included 6588 adults selected through a simple random population-based sample from the Health Service database of the Madrid Region (Spain). Adjusted prevalence rates were calculated by the direct method, according to Spanish population data from the National Institute of Statistics. The relationships of CKM disorders with coronary heart disease (CHD), stroke, peripheral arterial disease (PAD), and ASCVD were assessed by bivariate and multivariate analyses. Results: The age- and sex-adjusted prevalence rates among overall adults with CHD, stroke, PAD, and ASCVD were 3.8%, 3.0%, 1.8%, and 7.3%, respectively, and they reached 5.6%, 4.4%, 2.6%, and 10.8%, respectively, among people aged 40 years and older. The prevalence rates were higher in men than women aged over 40 years for CHD and ASCVD, between 50 and 69 years for stroke, and aged over 60 years for PAD. The mean ages of women and men with ASCVD were 74.9 and 70.2 years, respectively. Hypertension, heart failure (HF), hypercholesterolaemia, diabetes, low eGFR, atrial fibrillation (AF), prediabetes, and low HDL-c were independently associated with ASCVD, highlighting hypertension and HF for all of them, in addition to hypercholesterolaemia for CHD and stroke, and specifically, AF for stroke. Conclusions: More than one in ten people aged over 40 suffer from CHD, stroke, or PAD. Hypertension, HF, hypercholesterolaemia, diabetes, and low eGFR are the major CKM disorders associated with ASCVD.